Author of

• 10643

  +

  P1.07 - Poster Session 1 - Surgery (ID 184)

  • Event: WCLC 2013
  • Type: Poster Session
  • Track: Surgery
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/28/2013, 09:30 - 16:30, Exhibit Hall, Ground Level

  • 10668

    +

    P1.07-025 - Long-term Survival of Patients with cN2/pN2 Non-Small-Cell Lung Cancer (ID 2026)

    09:30 - 09:30  |  Author(s): K. Kim
    • Abstract

    Background
    Optimal management of stage IIIA-N2 non-small cell lung cancer (NSCLC) is controversial. However, surgery is used increasingly for stage IIIA NSCLC. We believe that surgical outcome of NSCLC patients with clinical N2 and pathological N2 (cN2/pN2) is worst among the NSCLC patients with cN2 disease. Analysis aimed at evaluating survival rates of patients with cN2/pN2 stage, and at studying prognostic factors for long-term survival.

    Methods
    This is a retrospective study of 72 NSCLC patients with cN2/pN2 stage who underwent surgery with neoadjuvant or adjuvant treatment from 2003 to 2011. Overall survival (OS) and disease-free survival (DFS) were estimated using Kaplan-Meier methods. A multivariate analysis for prognostic factors was performed by the Cox proportional hazards regression model.

    Results
    The median follow-up time was 24.5 months (range, 1 to 110 months) for 72 NSCLC patients. Neoadjuvant treatment was administered to 32 patients (44.4%), and adjuvant therapy was given to 40 patients (55.6%). Pneumonectomies were performed more frequently in patients who were treated with neoadjuvant therapy (25% vs. 15%). Complete resection was achieved more commonly in patients who underwent surgery followed adjuvant treatment (95% vs. 75%). Five year OS was 40.5% and 3-year DFS was 34.3%. In a multivariate analysis, incomplete resection was prognostic for a worse OS (hazard ratio: 3.07, 95% CI: 1.20 to 7.86). The more advanced pathological T stage was prognostic factor for a worse DFS (hazard ratio: 3.21, 95% CI: 1.42-7.24). Number of metastatic lymph node is important prognostic factor for OS and DFS.

    Conclusion
    Favorable survival can be achieved in cN2/pN2 NSCLC patients after resection with neoadjuvant therapy or adjuvant therapy. Survival is more favorable for complete resection than incomplete resection.